Merck's going through some bad times because of the Vioxx litigation but this is a legacy company that is built to weather such storms and come out of the other side leaner and meaner than its competitors. Merck has a significant drug which is a vaccination for the HPV virus that causes genital warts and cervical cancer. It has passed clinical trials and is ramping up for mass marketing. This is a multi-billion dollar global market which will help the company's 5-year growth prospects and position it better for growth in the next decade through major acquisitions.
$34.32 (04/27/06)
